Johnson & Johnson (NYSE:JNJ) Shares Sold by Fiduciary Group LLC

Fiduciary Group LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 6.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 86,411 shares of the company’s stock after selling 5,479 shares during the quarter. Johnson & Johnson accounts for about 1.3% of Fiduciary Group LLC’s holdings, making the stock its 18th largest holding. Fiduciary Group LLC’s holdings in Johnson & Johnson were worth $12,497,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Werba Rubin Papier Wealth Management raised its holdings in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after acquiring an additional 67 shares during the last quarter. Sage Mountain Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after acquiring an additional 67 shares during the last quarter. Corepath Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after acquiring an additional 70 shares during the last quarter. Finally, Lifestyle Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 4.7% during the fourth quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock valued at $226,000 after acquiring an additional 70 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Bank of America increased their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Trading Down 0.8 %

Shares of NYSE JNJ opened at $163.01 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $156.15 and a 200-day simple moving average of $156.30. The stock has a market capitalization of $392.83 billion, a PE ratio of 24.51, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.